Yukio Kageyama - Department of Urology, Saitama Cancer Center

基本信息

浏览量：99

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 102 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Immunostaining for Polycomb Group Protein EZH2 As a Diagnostic Tool to Differentiate Urothelial Carcinoma in Situ from Benign Lesions

Toshihiko Iizuka,Ayataka Ishikawa,Noriko Motoi,Hiroaki Kanda,Yukio Kageyama

Human pathology (2025): 105823-105823

引用0浏览0WOS引用

Gustave Roussy Immune Score Predicts Survival Outcome of Patients with Metastatic Urothelial Carcinoma Treated with Pembrolizumab: A Multicenter Study of 321 Patients (YUSHIMA Study)

K. Tanabe,K. Shuichiro,N. Katsushi, Y. Junji,O. Yukihiro,O. Tetsuo,T. Ryoji,N. Akira,Y. Masataka,T. Tetsuro,S. Kazutaka,S. Yasuyuki,K. Fumitaka,K. Yukio, T. Hajime,Y. Soichiro, F. Yasuhisa

European Urology (2024): S1729-S1730

引用0浏览0引用

MP53-13 REAL-WORD OUTCOMES OF MAINTENANCE CHEMOTHERAPY VERSUS AVELUMAB THERAPY AFTER FIRST-LINE INDUCTION CHEMOTHERAPY FOR ADVANCED UROTHELIAL CARCINOMA: YUSHIMA STUDY

Keita Izumi,Hajime Tanaka,Masataka Yano,Ryoji Takazawa,Akira Noro,Tetsuro Tsukamoto,Junji Yonese,Tetsuo Okuno,Yasuyuki Sakai,Fumitaka Koga,Yukio Kageyama,Kazutaka Saito,Yasuhisa Fujii

The Journal of Urology（2024）

引用0浏览0引用

STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer

Hirotaka Fuchizawa,Kiyohiro Ando,Noriko Motoi,Toshihiko Iizuka,Masaharu Inoue,Kouki Mitani, Yuta Sano,Hisanori Takenobu,Masayuki Haruta,Ritsuko Onuki,Yoh Matsuoka,Takehiko Kamijo,Yukio Kageyama

Anticancer Research（2024）

引用0浏览0WOS引用

Editorial Comment on Clinical Outcomes of Nivolumab Plus Ipilimumab in Patients with Metastatic Non‐clear Cell Renal Cell Carcinoma: Real‐world Data from a Japanese Multicenter Retrospective Study

Keita Izumi,Masaharu Inoue,Satoshi Washino,Suguru Shirotake,Makoto Kagawa,Hideki Takeshita,Yuji Miura,Yoji Hyodo,Masafumi Oyama,Satoru Kawakami,Tomoaki Miyagawa,Kazutaka Saito,Yukio Kageyama

INTERNATIONAL JOURNAL OF UROLOGY（2023）

引用5浏览0WOS引用

A Case of Immune Thrombocytopenia Occurring after Radiotherapy Plus Atezolizumab Treatment for Bladder Cancer

Yasunobu Sekiguchi, You Nishimura,Hiroaki Kanda,Machiko Kawamura,Kazuhiko Kobayashi,Koki Mitani,Ryo Kurashina,Riko Ikeda,Masaharu Inoue,Yoh Matsuoka,Yukio Kageyama, Yuki Akaba,Hirofumi Kobayashi

Gan to kagaku ryoho Cancer & chemotherapyno. 9 (2023): 985-992

引用0浏览0WOS引用

Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma

Ryo Kurashina,Kiyohiro Ando,Masaharu Inoue,Riko Maruyama,Kouki Mitani,Hisanori Takenobu,Masayuki Haruta,Ritsuko Onuki,Yoh Matsuoka,Takehiko Kamijo,Yukio Kageyama

Cancer Diagnosis & Prognosisno. 2 (2023): 230-235

引用7浏览0WOS引用

Positive Regulatory Loop of Platelet-Derived Growth Factor DD-induced STAT3 Activation is Associated with Poor Prognosis in Advanced Urothelial Carcinoma

Kiyohiro Ando,Ryo Kurashina,Noriko Motoi,Toshihiko Iizuka,Masaharu Inoue,Riko Maruyama,Kouki Mitani,Hisanori Takenobu,Masayuki Haruta,Ritsuko Onuki,Yoh Matsuoka,Takehiko Kamijo,Yukio Kageyama

Biochemical and Biophysical Research Communications (2023): 165-170

引用2浏览0WOS引用

Riko Ikeda,Yoh Matsuoka,Masaharu Inoue,Ayataka Ishikawa,Kiwamu Akagi,Yukio Kageyama

IJU Case Reportsno. 2 (2023): 115-119

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn